Holen Sie sich die Stockscreener-App
36.00
0.63%
-0.23
Handel nachbörslich:
36.48
0.48
+1.33%
Schlusskurs vom Vortag:
$36.23
Offen:
$36.53
24-Stunden-Volumen:
493.42K
Relative Volume:
0.48
Marktkapitalisierung:
$2.25B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-229.97M
KGV:
-8.3268
EPS:
-4.3234
Netto-Cashflow:
$-136.51M
1W Leistung:
+4.59%
1M Leistung:
-19.71%
6M Leistung:
+60.43%
1J Leistung:
+946.51%
1-Tages-Spanne:
$35.77
$36.91
1-Wochen-Bereich:
$34.49
$37.97
52-Wochen-Spanne:
$3.26
$47.84
Kodiak Sciences Inc Stock (KOD) Company Profile
Firmenname
Kodiak Sciences Inc
Sektor
Branche
Telefon
650-281-0850
Adresse
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
36.00 | 2.27B | 0 | -229.97M | -136.51M | -4.3234 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-25 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-09-22 | Eingeleitet | Jefferies | Buy |
| 2025-08-14 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2023-12-11 | Fortgesetzt | Goldman | Sell |
| 2023-11-17 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-25 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-15 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2022-02-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-11-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-03 | Eingeleitet | Goldman | Buy |
| 2020-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Eingeleitet | SunTrust | Buy |
| 2020-01-08 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-03 | Eingeleitet | Jefferies | Buy |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2018-10-29 | Eingeleitet | Barclays | Overweight |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Buy |
| 2018-10-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Kodiak Sciences Inc Aktie (KOD) Neueste Nachrichten
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally - AOL.com
KOD Technical Analysis | Trend, Signals & Chart Patterns | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Kodiak Sciences Inc stock (US50012K1051): earnings loss widens as biotech pushes retina pipeline - AD HOC NEWS
Kodiak Sciences Inc stock (US50012K1051): what’s behind the latest volatility after eye disease se - AD HOC NEWS
Boxer Capital Management Boosts Kodiak Sciences Holdings in Q1 2026News and Statistics - IndexBox
Kodiak Sciences Inc stock (US50012K1051): Investors eye eye-disease pipeline after latest company up - AD HOC NEWS
Kodiak Sciences stock hits 52-week highhere's why - MSN
Kodiak Sciences (KOD) price target increased by 16.91% to 66.30 - MSN
Sirenia Capital (KOD) and Alex Silverstein report 3,495,000 shares (5.7%) - Stock Titan
Kodiak Sciences stock (US50012K1051): Q4 2025 earnings miss sparks investor focus - AD HOC NEWS
Kodiak Sciences (KOD) up 2% since last earnings report: Can it continue? - MSN
J.P. Morgan Maintains Kodiak Sciences(KOD.US) With Buy Rating, Cuts Target Price to $56 - Moomoo
Number of shareholders of Kodiak Sciences Inc – NASDAQ:KOD - TradingView
Chardan Capital upgrades Kodiak Sciences (KOD) - MSN
TradingKey - TradingKey
Kodiak Sciences stock is surging Friday: What's driving the action? - MSN
KOD Upgraded by Chardan Capital -- Price Target Raised to $61.00 - GuruFocus
This Pitney Bowes Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
Chardan upgrades Kodiak Sciences stock rating on drug trial results By Investing.com - Investing.com South Africa
Chardan upgrades Kodiak Sciences stock rating on drug trial results - Investing.com
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58 - Moomoo
Kodiak's Q1 loss wider than expected, pipeline development in focus - MSN
A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda - Yahoo Finance
Zenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD) - Yahoo Finance
Kodiak Sciences Zenkuda Data Shifts Focus To Retinal Pipeline Value - Sahm
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
KOD SEC FilingsKodiak Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Cuts Target Price to $65 - Moomoo
Kodiak Sciences 1Q Loss/Shr 94c >KOD - Moomoo
Kodiak Sciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Kodiak Sciences (NASDAQ: KOD) Q1 loss deepens as cash runway, going concern risk flagged - Stock Titan
Kodiak Sciences (NASDAQ: KOD) posts Q1 loss, highlights strong Phase 3 data - Stock Titan
Kodiak Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
KOD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Press Release: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results - Moomoo
Kodiak Sciences (KOD) Expected to Announce Earnings on Wednesday - MarketBeat
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences - marketscreener.com
Kodiak Sciences Inc. $KOD Stock Holdings Decreased by RIA Advisory Group LLC - MarketBeat
Eye drug data from Taiwan cohort backs Kodiak Phase 3 expansion - Stock Titan
Kodiak Sciences Presents Pipeline Advances and KSI-101 Clinical Data At Scientific Conferences - marketscreener.com
Finanzdaten der Kodiak Sciences Inc-Aktie (KOD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kodiak Sciences Inc-Aktie (KOD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | Chief Financial Officer |
Apr 02 '26 |
Option Exercise |
1.04 |
30,000 |
31,200 |
213,316 |
| BORGESON JOHN A. | Chief Financial Officer |
Apr 02 '26 |
Sale |
39.92 |
30,000 |
1,197,488 |
183,316 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):